Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adibelizumab plus bevacizumab and chemotherapy for driver gene–negative non-squamous NSCLC with brain metastases
ChiCTR2500113887Phase 4Recruiting
- Sponsor
- Meizhou People's Hospital
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in Non-small cell lung cancer (NS-NSCLC) and brain metastases, sponsored by Meizhou People's Hospital. Primary endpoint: Intracranial progression-free survival (iPFS). Started Dec 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2500113887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113887.